[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1603862A1 - 3,3-diarylpropylamine derivatives and processes for isolation thereof - Google Patents

3,3-diarylpropylamine derivatives and processes for isolation thereof

Info

Publication number
EP1603862A1
EP1603862A1 EP04718361A EP04718361A EP1603862A1 EP 1603862 A1 EP1603862 A1 EP 1603862A1 EP 04718361 A EP04718361 A EP 04718361A EP 04718361 A EP04718361 A EP 04718361A EP 1603862 A1 EP1603862 A1 EP 1603862A1
Authority
EP
European Patent Office
Prior art keywords
tolterodine
pharmaceutically acceptable
acceptable salt
dimer
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04718361A
Other languages
German (de)
French (fr)
Inventor
Yatendra Kumar
Mohan Prasad
Neela Praveen Kumar
Kaushal Nayyar
Satyananda Misra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1603862A1 publication Critical patent/EP1603862A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives

Definitions

  • the field of the invention relates to 3,3-diarylpropylamines derivatives and processes for producing them. More particularly, it relates to the preparation of pure tolterodine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions that include the pure tolterodine or a pharmaceutically acceptable salt thereof. It also relates to a novel 3,3-dia ⁇ ylpropylamine derivative, referred to as tolterodine dimer. Chemically, tolterodine dimer is N,N-di-[3-[2-hydroxy-5-methylphenyl]-3- phenylpropyl]isopropylamine and has structural Formula I,
  • the invention also relates to use of pure tolterodine or a pharmaceutically acceptable salt thereof or tolterodine dimer as reference standards or reference markers for checking the purity of tolterodine.
  • Tolterodine is a new potent and competitive muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and other symptoms of bladder over activity.
  • tolterodine tartrate is L-(+)-tartrate salt of (+)-R-3(2-hydroxy-5- methylphenyl), N, N-diisopropyl-3-phenylpropyl amine and has structural Formula II.
  • Tolterodine dimer has a possibility of being used as a reference marker compound in identifying the purity of the tolterodine or a pharmaceutically acceptable salt thereof.
  • impurities in pharmaceutically active agents and formulations containing them include residual amounts of synthetic precursors to the active agent, by- products which arise during synthesis of the active agent, residual solvents, isomers of active agent, excipients used in the preparation of the pharmaceutical formulation, and unidentified adventitious substances.
  • Other impurities which may appear on storage include substances resulting from degradation of the active agent, for instance by oxidation or hydrolysis. Tolterodine easily forms dimer. However, there is no reference of the tolterodine dimer in the literature.
  • tolterodine dimer a novel 3,3-diarylpropylamines derivative, which is chemically N,N-di-[3-[2-hydroxy-5-methylphenyl]-3-phenylpropyl] isopropylamine of Formula I (hereinafter referred to as tolterodine dimer).
  • tolterodine dimer as a reference standard for determination of the purity of tolterodine or a pharmaceutically acceptable salt thereof.
  • composition that includes a therapeutically effective amount of pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer; and one or more pharmaceutically acceptable carriers, excipients or diluents.
  • composition that includes a therapeutically effective amount of pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer; and one or more pharmaceutically acceptable carriers, excipients or diluents.
  • a process of depletion of tolterodine dimer impurity from tolterodine or a pharmaceutically acceptable salt thereof includes obtaining a solution of crude tolterodine or a pharmaceutically acceptable salt thereof in one or more solvents; and recovering the pure tolterodine or a pharmaceutically acceptable salt thereof by the removal of the solvent.
  • the solvent maybe one or more of lower alkanol, ketone, polar aprotic solvent, or mixtures thereof.
  • the lower alkanol may include one or more of primary, secondary and tertiary alcohol having from one to six carbon atoms.
  • the lower alkanol may include one or more of methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol and t-butanol.
  • the ketone may include one or more of acetone, 2-butanone, and 4-methylpentan-
  • the polar aprotic solvent may include one or more of tetrahydrofuran, acetonitrile,
  • Removing the solvent may include one or more of distillation, distillation under vacuum, filtration, filtration under vacuum, decantation and centrifugation.
  • the process may include further drying of the product obtained.
  • the solution of crude tolterodine may be obtained by heating the solvent containing crude tolterodine. It maybe heated from about 30°C to about reflux temperature of the solvent used, for example from about 30°C to about 100°C. particular, it may be heated from about 40°C to about 60°C. It may be heated from about 15 minutes to about 10 hours. More particularly, it may be heated for about 2-3 hours.
  • the solution containing the crude tolterodine may be treated with charcoal before removing the solvent.
  • the charcoal treatment may be carried out under heating conditions or it may be carried out at a lower temperature.
  • additional/another solvent may be added to residue obtained after removal of the solvent and it may be cooled before filtration to obtain better yields of the pure tolterodine.
  • the process may produce the pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer. In particular, it may produce the pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer.
  • the inventors have identified that the tolterodine dimer is formed as an impurity during the synthesis of tolterodine or a pharmaceutically acceptable salt thereof.
  • the inventors have isolated tolterodine dimer which can be used as a reference standard for determination of the purity of tolterodine or a pharmaceutically acceptable salt thereof.
  • the process involves
  • N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine may be heated at reflux temperature for 10-12 hours with hydrobromic acid in the presence of acetic acid.
  • the reaction mass may be cooled to ambient temperature and the precipitated product may be isolated by conventional means and dried.
  • the crude product so obtained may be repeatedly loaded on YMC-Pack ODS-A (500 x 30 mm I. D.) column.
  • Mobile phase used may be a gradient of phosphate buffer (2gm KH2PO4 / lit of distilled water) and acetonitrile in 8:2 to 2:8 v/v ratio.
  • the fractions containing the dimer impurity may be further combined and concentrated to dryness.
  • the pure tolterodine dimer can then be further purified by crystallization or column chromatography.
  • the inventors also have developed a process of depletion of tolterodine dimer impurity from tolterodine or a pharmaceutically acceptable salt thereof, by obtaining a solution of crude tolterodine or a pharmaceutically acceptable salt thereof in one or more solvents; and recovering the pure tolterodine or a pharmaceutically acceptable salt thereof by the removal of the solvent.
  • the inventors also have developed pharmaceutical compositions that contain the pure tolterodine or a phanuaceutically acceptable salt thereof containing less than 0.5% tolterdine dimer, for example, less than 0.05% tolterodine dimer, in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients. These pharmaceutical compositions may be used for treating a patient in need of a treatment for urinary urge incontinence and other symptoms of bladder over activity.
  • the tolterodine or a pharmaceutically acceptable salt thereof may be prepared by the methods known in the literature. In particular, it may be prepared using the reactions and techniques described in our PCT patent application WO 03/014060 which is incorporated herein as reference.
  • the solution of crude tolterodine may be obtained by dissolving crude tolterodine in a suitable solvent. Alternatively, such a solution may be obtained directly from a reaction in which tolterodine is formed.
  • the solvent containing crude tolterodine may be heated to obtain a solution. It can be heated from about 30°C to about reflux temperature of the solvent used, for example from about 30°C to about 100°C. h particular, it can be heated from about 40°C to about 60°C. It can be heated from about 15 minutes to about 10 hours. More particularly, it can be heated for about 2-3 hours.
  • the product may be isolated from the solution by a technique which includes, for example, distillation, distillation under vacuum, filtration, filtration under vacuum, decantation, and centrifugation.
  • suitable solvent includes any solvent or solvent mixture in which crude tolterodine is soluble, including, for example, lower alkanol, ketone, polar aprotic solvent and mixtures thereof.
  • alkanol include those primary, secondary and tertiary alcohols having from one to six carbon atoms.
  • Suitable lower alkanol solvents include methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol and t- butanol.
  • a suitable ketone includes one or more of acetone, 2-butanone, and 4- methylpentan-2-one.
  • polar aprotic solvents include solvents such as tetrahydrofuran, acetonitrile, 1,4-dioxane and N-methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
  • the solution containing crude tolterodine can be treated with activated carbon and filtered while hot.
  • additional or another solvent can be added to the clear solution to precipitate the pure tolterodine or a pharmaceutically acceptable salt thereof.
  • the product obtained may be further or additionally dried to achieve the desired moisture values.
  • the product may be further or additionally dried in a tray drier, dried under vacuum and/or in a Fluid Bed Drier.
  • the solution containing the crude tolterodine may be heated for dissolution, or may be cooled to separate out the product or the slurry may further be cooled prior to filtration or the solution may be seeded with seed crystals of the product to enhance precipitation of the product.
  • the crude product was repeatedly loaded on YMC-Pack ODS-A (500 x 30 mm I. D.) column.
  • Mobile phase used was gradient of phosphate buffer (2gm KH2PO4 / lit of distilled water) and acetonitrile 8:2 to 2:8.
  • the fractions containing the dimer impurity were combined and concentrated to dryness.
  • the spectral data of the isolated tolterodine dimer are as follows:
  • Tolterodine hydrobromide (230 g) from Example 1 (HPLC Purity: 97.52%), methylene chloride and water were mixed. The pH was adjusted to about 10 - 11 while adding sodium hydroxide (50%, 21 g in 42 ml) and sodium carbonate (26.45 g). After stirring for about 15 minutes, two clear homogeneous phases were formed. The organic layer was separated and washed with water twice (2 x 1150 ml), and was concentrated under reduced pressure. The concentrate was dissolved in acetone (1150 ml) and warmed to 50°C.
  • Acetone (2.2 lit.) was added at reflux temperature and gradually cooled to 20 - 25°C. The solid was filtered and washed with acetone (440 ml) and dried under reduced pressure to give pure (R) tolterodine-L-tartrate.
  • Tolterodine hydrobromide (230 g) from Example 2 (HPLC Purity: 98.37%), methylene chloride and water were mixed. The pH was adjusted to about 10 - 11 while adding sodium hydroxide (50%, 21 g in 42 ml) and sodium carbonate (26.45 g). After stirring for 15 minutes, two clear homogeneous phases were formed. The organic layer was separated and washed with water twice (2 x 1150 ml), and concentrated under reduced pressure. The concentrate was dissolved in acetone (1150 ml) and warmed to 50°C.
  • Tolterodine hydrobromide (230 g) from Example 3 (HPLC Purity: 95.92%), methylene chloride and water were mixed. The pH was adjusted to about 10 - 11 while adding sodium hydroxide (50%, 21 g in 42 ml) and sodium carbonate (26.45 g). After stirring for 15 minutes, two clear homogeneous phases were formed. The organic layer was separated and washed with water twice (2 x 1150 ml), and concentrated under reduced pressure. The concentrate was dissolved in acetone (1150 ml) and warmed to 50°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 3,3-diarylpropylamines derivatives and processes for producing them. More particularly, it relates to the preparation of pure tolterodine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions that include the pure tolterodine or a pharmaceutically acceptable salt thereof. It also relates to a novel 3,3­diarylpropylamine derivative, referred to as tolterodine dimer. Chemically, tolterodine dimer is N,N-di-[3-[2-hydroxy-5-methylphenyl]-3-phenylpropyl]isopropylamine and has structural Formula (I), The invention also relates to use of pure tolterodine or tolterodine dimer as reference standards or reference markers for checking the purity of tolterodine.

Description

3,3-DIARYLPROPYLAMINE DERIVATIVES AND PROCESSES FOR
ISOLATION THEREOF
Field of the Invention
The field of the invention relates to 3,3-diarylpropylamines derivatives and processes for producing them. More particularly, it relates to the preparation of pure tolterodine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions that include the pure tolterodine or a pharmaceutically acceptable salt thereof. It also relates to a novel 3,3-diaιylpropylamine derivative, referred to as tolterodine dimer. Chemically, tolterodine dimer is N,N-di-[3-[2-hydroxy-5-methylphenyl]-3- phenylpropyl]isopropylamine and has structural Formula I,
FORMULA I
The invention also relates to use of pure tolterodine or a pharmaceutically acceptable salt thereof or tolterodine dimer as reference standards or reference markers for checking the purity of tolterodine.
Background of the Invention
Tolterodine is a new potent and competitive muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and other symptoms of bladder over activity.
Chemically, tolterodine tartrate is L-(+)-tartrate salt of (+)-R-3(2-hydroxy-5- methylphenyl), N, N-diisopropyl-3-phenylpropyl amine and has structural Formula II. L-(+)-tartaric acid
FORMULA II
In order to secure marketing approval for a new drug product, a drug manufacturer must submit detailed evidence to the appropriate regulatory authorities to show that the product is suitable for release on to the market. The regulatory authorities must be satisfied, inter alia that the active agent is acceptable for administration to humans and that the particular formulation which is to be marketed is free from impurities at the time of release and has an appropriate shelf-life.
Submissions made to regulatory authorities therefore typically include analytical records, which demonstrate:
(a) that impurities are absent from the drug at the time of manufacture, or are present only at negligible level, and
(b) that the storage stability i.e., shelf-life of the drug is acceptable.
These details are usually obtained by testing the drug against an external standard, or reference marker, which is a pure sample of a potential impurity or a potential degradation product. Tolterodine dimer has a possibility of being used as a reference marker compound in identifying the purity of the tolterodine or a pharmaceutically acceptable salt thereof.
Potential impurities in pharmaceutically active agents and formulations containing them include residual amounts of synthetic precursors to the active agent, by- products which arise during synthesis of the active agent, residual solvents, isomers of active agent, excipients used in the preparation of the pharmaceutical formulation, and unidentified adventitious substances. Other impurities which may appear on storage include substances resulting from degradation of the active agent, for instance by oxidation or hydrolysis. Tolterodine easily forms dimer. However, there is no reference of the tolterodine dimer in the literature.
Summary of the Invention
In one general aspect there is provided a novel 3,3-diarylpropylamines derivative, which is chemically N,N-di-[3-[2-hydroxy-5-methylphenyl]-3-phenylpropyl] isopropylamine of Formula I (hereinafter referred to as tolterodine dimer).
In another general aspect there is provided use of tolterodine dimer as a reference standard for determination of the purity of tolterodine or a pharmaceutically acceptable salt thereof.
h another general aspect there is provided a process for the isolation of tolterodine dimer.
In another general aspect there is provided a pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer.
In another aspect there is provide a pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer.
In another aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer; and one or more pharmaceutically acceptable carriers, excipients or diluents.
i another aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer; and one or more pharmaceutically acceptable carriers, excipients or diluents.
In another aspect there is provided a process of depletion of tolterodine dimer impurity from tolterodine or a pharmaceutically acceptable salt thereof. The process includes obtaining a solution of crude tolterodine or a pharmaceutically acceptable salt thereof in one or more solvents; and recovering the pure tolterodine or a pharmaceutically acceptable salt thereof by the removal of the solvent. The solvent maybe one or more of lower alkanol, ketone, polar aprotic solvent, or mixtures thereof. The lower alkanol may include one or more of primary, secondary and tertiary alcohol having from one to six carbon atoms. The lower alkanol may include one or more of methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol and t-butanol.
The ketone may include one or more of acetone, 2-butanone, and 4-methylpentan-
2-one. The polar aprotic solvent may include one or more of tetrahydrofuran, acetonitrile,
1,4-dioxane and N-methylpyrrolidone. Removing the solvent may include one or more of distillation, distillation under vacuum, filtration, filtration under vacuum, decantation and centrifugation.
The process may include further drying of the product obtained.
In one general aspect, the solution of crude tolterodine may be obtained by heating the solvent containing crude tolterodine. It maybe heated from about 30°C to about reflux temperature of the solvent used, for example from about 30°C to about 100°C. particular, it may be heated from about 40°C to about 60°C. It may be heated from about 15 minutes to about 10 hours. More particularly, it may be heated for about 2-3 hours.
In one general aspect the solution containing the crude tolterodine may be treated with charcoal before removing the solvent. The charcoal treatment may be carried out under heating conditions or it may be carried out at a lower temperature.
i another general aspect additional/another solvent may be added to residue obtained after removal of the solvent and it may be cooled before filtration to obtain better yields of the pure tolterodine.
The process may produce the pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer. In particular, it may produce the pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer.
hi another aspect there is provided a method of treating urinary urge incontinence and other symptoms of bladder over activity using therapeutically effective amount of the pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer.
In another aspect there is provided a method of treating urinary urge incontinence and other symptoms of bladder over activity using therapeutically effective amount of the pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
Detailed Description of the Invention
The inventors have identified that the tolterodine dimer is formed as an impurity during the synthesis of tolterodine or a pharmaceutically acceptable salt thereof. The inventors have isolated tolterodine dimer which can be used as a reference standard for determination of the purity of tolterodine or a pharmaceutically acceptable salt thereof.
The process involves
a) heating N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3- phenylpropylamine of Formula III with aqueous hydrobromic acid in the presence of acetic acid to get crude tolterodine hydrobromide,
FORMULA III
b) subjecting the crude tolterodine hydrobromide to preparative HPLC and eluting with a gradient mobile phase to get eluent containing tolterodine dimer, and
c) isolating the pure tolterodine dimer from the eluent. N, N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine may be heated at reflux temperature for 10-12 hours with hydrobromic acid in the presence of acetic acid. The reaction mass may be cooled to ambient temperature and the precipitated product may be isolated by conventional means and dried. The crude product so obtained may be repeatedly loaded on YMC-Pack ODS-A (500 x 30 mm I. D.) column. Mobile phase used may be a gradient of phosphate buffer (2gm KH2PO4 / lit of distilled water) and acetonitrile in 8:2 to 2:8 v/v ratio. The fractions containing the dimer impurity may be further combined and concentrated to dryness. The pure tolterodine dimer can then be further purified by crystallization or column chromatography.
The inventors also have developed a process of depletion of tolterodine dimer impurity from tolterodine or a pharmaceutically acceptable salt thereof, by obtaining a solution of crude tolterodine or a pharmaceutically acceptable salt thereof in one or more solvents; and recovering the pure tolterodine or a pharmaceutically acceptable salt thereof by the removal of the solvent. The inventors also have developed pharmaceutical compositions that contain the pure tolterodine or a phanuaceutically acceptable salt thereof containing less than 0.5% tolterdine dimer, for example, less than 0.05% tolterodine dimer, in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients. These pharmaceutical compositions may be used for treating a patient in need of a treatment for urinary urge incontinence and other symptoms of bladder over activity.
The tolterodine or a pharmaceutically acceptable salt thereof may be prepared by the methods known in the literature. In particular, it may be prepared using the reactions and techniques described in our PCT patent application WO 03/014060 which is incorporated herein as reference.
h general, the solution of crude tolterodine may be obtained by dissolving crude tolterodine in a suitable solvent. Alternatively, such a solution may be obtained directly from a reaction in which tolterodine is formed. The solvent containing crude tolterodine may be heated to obtain a solution. It can be heated from about 30°C to about reflux temperature of the solvent used, for example from about 30°C to about 100°C. h particular, it can be heated from about 40°C to about 60°C. It can be heated from about 15 minutes to about 10 hours. More particularly, it can be heated for about 2-3 hours. The product may be isolated from the solution by a technique which includes, for example, distillation, distillation under vacuum, filtration, filtration under vacuum, decantation, and centrifugation.
The term "suitable solvent" includes any solvent or solvent mixture in which crude tolterodine is soluble, including, for example, lower alkanol, ketone, polar aprotic solvent and mixtures thereof. Examples of alkanol include those primary, secondary and tertiary alcohols having from one to six carbon atoms. Suitable lower alkanol solvents include methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol and t- butanol.
A suitable ketone includes one or more of acetone, 2-butanone, and 4- methylpentan-2-one. Examples of polar aprotic solvents include solvents such as tetrahydrofuran, acetonitrile, 1,4-dioxane and N-methylpyrrolidone. Mixtures of all of these solvents are also contemplated.
h one aspect, the solution containing crude tolterodine can be treated with activated carbon and filtered while hot.
h another aspect, additional or another solvent can be added to the clear solution to precipitate the pure tolterodine or a pharmaceutically acceptable salt thereof.
The product obtained may be further or additionally dried to achieve the desired moisture values. For example, the product may be further or additionally dried in a tray drier, dried under vacuum and/or in a Fluid Bed Drier.
Methods known in the art may be used with the process of this invention to enhance any aspect of this invention. For example, the solution containing the crude tolterodine may be heated for dissolution, or may be cooled to separate out the product or the slurry may further be cooled prior to filtration or the solution may be seeded with seed crystals of the product to enhance precipitation of the product.
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and are not intended to limit the scope of the invention. Although the examples are directed to the tolterodine hydrobromide and tolterodine tartrate, the principles described in these examples can be applied to other salts of tolterodine. Example 1
Preparation of tolterodine hydrobromide
N,N-diisopropyl-3 -(2-methoxy-5-methylphenyl)-3 -phenylpropyl amine (HPLC Purity, 97.41%) (225 g, 0.663 mol) was heated with aqueous hydrobromic acid (500 ml) and acetic acid (300 ml) to a reflux temperature (110-115°C) for 10-12 hours. The reaction mixture was cooled to room temperature, maintained for 1 hour and then filtered. The product so obtained was washed with water and dried under vacuum to yield the titled product. (234 g) in 86% yield;
Purity (by HPLC): 97.52%.
Dimeric Impurity: 1.29%,
The crude product was repeatedly loaded on YMC-Pack ODS-A (500 x 30 mm I. D.) column. Mobile phase used was gradient of phosphate buffer (2gm KH2PO4 / lit of distilled water) and acetonitrile 8:2 to 2:8. The fractions containing the dimer impurity were combined and concentrated to dryness. The spectral data of the isolated tolterodine dimer are as follows:
1H-NMR (300 MHz) in DMSO-D6, Dppm: 0.85 (d, 3H, -CH-CH3); 1.1 (d, 3H, - CH-CH3); 2.06-2.37 (m, 10H, 2x -CH3, 2x -CH2); 2.73-3.17 (m, 5H, 2x -CH2, -CH-CH3); 4.27 (m, 2H, 2x Ar-CH-Ar); 6.64 (d, 2H, 2x -C3' H); 6.70 (d, 2H, 2x -CV H); 6.75 (s, 2H, 2x -C6' H); 7.20 (m, 10H, Ar)
MASS: 508.1 (M +1)
MS/MS: 466.0, 284.1, 197.1, 147.0, and 121.0
Example 2
Preparation of tolterodine hydrobromide
N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropyl amine 225 g (HPLC Purity : 98.57%) was heated with aqueous hydrobromic acid (500 ml) and acetic acid to reflux temperature (110 -115°C) for 10 -12 hours. The reaction mixture was cooled to room temperature, maintained for 1 hour and then filtered. The product obtained was washed with water and dried under vacuum to yield the product 237.35 g.
HPLC Purity: 98.37%.
Dimeric Impurity: 0.75%
Example 3
Preparation of tolterodine hydrobromide
N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropyl amine 225 g (HPLC Purity: 96.31) was heated with aqueous hydrobromic acid (500 ml) and acetic acid to reflux temperature (110 -115°C) for 10 -12 hours. The reaction mixture was cooled to room temperature, maintained for 1 hour and then filtered. The product obtained was washed with water and dried under vacuum to yield the product 233 g.
HPLC Purity: 95.92%
Dimeric Impurity: 2.86%
Example 4
Preparation of tolterodine tartrate
Tolterodine hydrobromide (230 g) from Example 1 (HPLC Purity: 97.52%), methylene chloride and water were mixed. The pH was adjusted to about 10 - 11 while adding sodium hydroxide (50%, 21 g in 42 ml) and sodium carbonate (26.45 g). After stirring for about 15 minutes, two clear homogeneous phases were formed. The organic layer was separated and washed with water twice (2 x 1150 ml), and was concentrated under reduced pressure. The concentrate was dissolved in acetone (1150 ml) and warmed to 50°C. The L-tartaric acid solution (126.5 g) dissolved in 575 ml methanol was added over about 30 minutes, followed by refluxing the slurry for 1 hour and was gradually cooled to 20 - 25°C. The mixture was filtered and washed with acetone (460 ml) and dried under reduced pressure to give crude tolterodine tartrate.
Yield (w/w): l 18 g HPLC Purity (%): 99.48
Dimeric Impurity (%): 0.33
The crude tolterodine tartrate (110 g) and methanol (1270 ml) were heated to reflux for 30 minutes. Charcoal was added to the solution and stirred for 1 hour at reflux temperature. The solution was filtered, and the mixture was concentrated to 1100 ml.
Acetone (2.2 lit.) was added at reflux temperature and gradually cooled to 20 - 25°C. The solid was filtered and washed with acetone (440 ml) and dried under reduced pressure to give pure (R) tolterodine-L-tartrate.
Yield (w/w): 80.5 g
HPLC Purity (%): 99.90
Dimeric Impurity (%): 0.06
Example 5
Preparation of tolterodine tartrate
Tolterodine hydrobromide (230 g) from Example 2 (HPLC Purity: 98.37%), methylene chloride and water were mixed. The pH was adjusted to about 10 - 11 while adding sodium hydroxide (50%, 21 g in 42 ml) and sodium carbonate (26.45 g). After stirring for 15 minutes, two clear homogeneous phases were formed. The organic layer was separated and washed with water twice (2 x 1150 ml), and concentrated under reduced pressure. The concentrate was dissolved in acetone (1150 ml) and warmed to 50°C. The L-tartaric acid solution (126.5 g) dissolved in 575 ml methanol was added over about 30 minutes followed by refluxing the slurry for 1 hour and was gradually cooled to 20 - 25°C. The mixture was filtered and washed with acetone (460 ml) and dried under reduced pressure to give crude tolterodine tartrate.
Yield (w/w): 120 g
HPLC Purity (%): 99.66
Dimeric hnpurity (%): 0.18
The crude tolterodine tartrate (110 g) and methanol (1270 ml) were heated to reflux for 30 minutes. Charcoal was added to the solution and stirred for 1 hour at reflux temperature. The solution was filtered, and the mixture concentrated to 1100 ml. Acetone (2.2 lit.) was added at reflux temperature and gradually cooled to 20 - 25°C. The solid was filtered and washed with acetone (440 ml) and dried under reduced pressure to pure (R) tolterodine-L-tartrate.
Yield (w/w): 81 g
HPLC Purity (%): 99.903
Dimeric Impurity (%): 0.035
Example 6
Preparation of tolterodine tartrate
Tolterodine hydrobromide (230 g) from Example 3 (HPLC Purity: 95.92%), methylene chloride and water were mixed. The pH was adjusted to about 10 - 11 while adding sodium hydroxide (50%, 21 g in 42 ml) and sodium carbonate (26.45 g). After stirring for 15 minutes, two clear homogeneous phases were formed. The organic layer was separated and washed with water twice (2 x 1150 ml), and concentrated under reduced pressure. The concentrate was dissolved in acetone (1150 ml) and warmed to 50°C. The L-tartaric acid solution (126.5 g) dissolved in 575 ml methanol was added over about 30 minutes followed by refluxing the slurry for 1 hour and was gradually cooled to 20 - 25 °C. The mixture was filtered and washed with acetone (460 ml) and dried under reduced pressure to give crude tolterodine tartrate.
Yield (w/w): 115 g
HPLC Purity (%): 99.21
Dimeric Impurity (%): 0.60
The crude tolterodine tartrate (110 g) and methanol (1270 ml) were heated to reflux for 30 minutes. Charcoal was added to the solution and stirred for 1 hour at reflux temperature. The solution was filtered, and the mixture concentrated to 1100 ml. The acetone (2.2 lit.) was added at reflux temperature and was gradually cooled to 20 - 25°C. The solid was filtered and washed with acetone (440 ml) and dried under reduced pressure to pure (R) tolterodine-L-tartrate.
Yield (w/w): 82.5 g
HPLC Purity (%): 99.819
Dimeric Impurity (%): 0.10
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

We claim:
1. Tolterodine dimer, N,N-di-[3-[2-hydroxy-5-methylphenyl]-3-phenylpropyl] isopropylamine of Formula I
FORMULA I
2. A method of determining purity of tolterodine or a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the same, which comprises use of tolterodine dimer of Formula I as a reference standard compound.
A process for the isolation of tolterodine dimer, the process comprising
a) heating N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3- phenylpropylamine of Formula III with aqueous hydrobromic acid in the presence of acetic acid to get crude tolterodine hydrobromide,
FORMULA III
b) subjecting the crude tolterodine hydrobromide to preparative HPLC and eluting with a gradient mobile phase to get eluent containing tolterodine dimer, and
c) isolating the pure tolterodine dimer from the eluent.
4. The process of claim 3, wherein the crude tolterodine hydrobromide is repeatedly loaded on YMC-Pack ODS-A (500 x 30 mm I. D.) HPLC column and eluted using gradient mobile phase of phosphate buffer and acetonitrile.
5. A process of depletion of tolterodine dimer impurity from tolterodine or a pharmaceutically acceptable salt thereof, the process comprising obtaining a solution of crude tolterodine or a pharmaceutically acceptable salt thereof in one or more solvent; and recovering the pure tolterodine or a pharmaceutically acceptable salt thereof by the removal of the solvent.
6. The process of claim 5, wherein the solution of crude tolterodine is obtained by heating the solvent.
7. The process of claim 6, wherein the heating temperature ranges from about 30°C to about 100°C.
8. The process of claim 7, wherein the heating temperature ranges from about 40°C to about 60°C.
9. The process of claim 5, wherein the solvent comprises one or more of lower alkanol, ketone, polar aprotic solvent, or mixtures thereof.
10. The process of claim 9, wherein the lower alkanol comprises one or more of primary, secondary and tertiary alcohols having from one to six carbon atoms.
11. The process of claim 10, wherein the lower alkanol comprises one or more of methanol, ethanol, denatured spirit, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol.
12. The process of claim 9, wherein the ketone comprises one or more of acetone, 2-butanone, and 4-methylpentan-2-one.
13. The process of claim 9, wherein the polar aprotic solvent comprises one or more of tetrahydrofuran, acetonitrile, 1,4-dioxane and N-methylpyrrolidone.
14. The process of claim 5, wherein removing the solvent comprises one or more of distillation, distillation under vacuum, filtration, filtration under vacuum, decantation, and centrifugation.
15. The process of claim 5, further comprising additional drying of the product obtained.
16. The process of claim 5, further comprising forming the product obtained into a finished dosage form.
17. A method of treating urinary urge incontinence or other symptoms of bladder over activity, the method comprising providing a dosage form that includes pure tolterodine or a pharmaceutically acceptable salt thereof prepared by the process of claim 5.
18. Tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer impurity when determined by HPLC.
19. Tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer impurity when determined by HPLC.
20. A pharmaceutical composition comprising a therapeutically effective amount of pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer; and one or more pharmaceutically acceptable carriers, excipients or diluents.
21. A pharmaceutical composition comprising a therapeutically effective amount of pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer; and one or more pharmaceutically acceptable carriers, excipients or diluents.
22. A method of treating urinary urge incontinence or other symptoms of bladder over activity, the method comprising providing a dosage form that includes pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.5% tolterodine dimer.
23. A method of treating urinary urge incontinence or other symptoms of bladder over activity, the method comprising providing a dosage form that includes pure tolterodine or a pharmaceutically acceptable salt thereof containing less than 0.05% tolterodine dimer.
EP04718361A 2003-03-06 2004-03-08 3,3-diarylpropylamine derivatives and processes for isolation thereof Withdrawn EP1603862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE02372003 2003-03-06
IN237DE2003 2003-03-06
PCT/IB2004/000638 WO2004078700A1 (en) 2003-03-06 2004-03-08 3,3-diarylpropylamine derivatives and processes for isolation thereof

Publications (1)

Publication Number Publication Date
EP1603862A1 true EP1603862A1 (en) 2005-12-14

Family

ID=32948050

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04718361A Withdrawn EP1603862A1 (en) 2003-03-06 2004-03-08 3,3-diarylpropylamine derivatives and processes for isolation thereof

Country Status (4)

Country Link
EP (1) EP1603862A1 (en)
AU (1) AU2004218178A1 (en)
CA (1) CA2517824A1 (en)
WO (1) WO2004078700A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527923A (en) * 2005-01-10 2007-10-04 テバ ファーマシューティカル インダストリーズ リミティド Method for preparing tolterodine tartrate
AR057333A1 (en) * 2005-05-27 2007-11-28 Medichem Sa PROCESS FOR THE PREPARATION OF 3,3-DIARILPROPILAMINS
WO2010092500A2 (en) 2009-02-12 2010-08-19 Alembic Limited A process for the preparation of tolterodine tartrate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (en) * 1988-01-22 1988-01-22 Kabivitrum Ab NEW AMINES, THEIR USE AND MANUFACTURING
KR20000057548A (en) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 Optically transmissive material and bond
IN191835B (en) * 2001-08-03 2004-01-10 Ranbaxy Lab Ltd

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004078700A1 *

Also Published As

Publication number Publication date
WO2004078700A1 (en) 2004-09-16
AU2004218178A1 (en) 2004-09-16
CA2517824A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
CN109563099B (en) Crystal form of compound, preparation and application thereof
US8969558B2 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2324027B1 (en) New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
EP2300479B1 (en) Nalmefene hydrochloride dihydrate
US9233972B2 (en) Preparation of 14-hydroxycodeinone sulfate
US20130158265A1 (en) Sitagliptin, salts and polymorphs thereof
CZ295477B6 (en) Process for preparing tolterodine
US20230219892A1 (en) Forms and compositions of a beta adrenergic agonist
US9062062B1 (en) Synthesis of oxycodone hydrochloride
AU2018202623A1 (en) Oxalate salts of Teneligliptin and solvates thereof, intermediates, process of prepration and markers thereof
WO2015095585A2 (en) Sysnthesis of oxycodone hydrochloride
US20150166552A1 (en) Conversion of oxycodone base to oxycodone hydrochloride
WO2004078700A1 (en) 3,3-diarylpropylamine derivatives and processes for isolation thereof
US11760730B2 (en) Process for the preparation of high purity Levosimendan
CN114341155A (en) Preparation method of peptide amide compound and intermediate thereof
CN107428761B (en) The method for preparing dipeptidyl peptidase-4 (DPP-4) inhibitor
FR2470129A1 (en) PROCESS FOR THE PREPARATION OF APOVINCAMINIC ACID ESTERS DERIVATIVES
US20230286900A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
US20060293517A1 (en) Enantiomerically pure cilazapril, process for preparation
EP2300473B1 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061003